Despite these differences, the authors found that chemotaxis and electrotaxis share a dependence on similar intracellular signaling molecules, most notably the phosphoinositide 3-kinase (PI3K ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

The Swiss drugmaker announced the global phase 3 SOLAR-1 trial evaluating the alpha-specific PI3K inhibitor codenamed BYL719 (alpelisib) has met the primary target and improved progression-free ...

The current PI3K 3C inhibitors in use in advanced breast cancer are alpelisib and inavolisib. Capivasertib is an AKT inhibitor, which is also used in PI3K 3C mutated breast cancer. So these are ...

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.